First phase 3 trial of a chikungunya vaccine candidate finds it is generally safe and provokes an immune response
The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% or (263/266) of participants, according to a phase 3 randomised controlled trial published in The Lancet. Because the study, VLA1553-301, was not conducted in regions where chikungunya is endemic, researchers were unable to investigate whether the vaccine…